Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-Blind, Randomized, Parallel-Group, Phase III Study of the Efficacy and Safety of Hercules Plus Taxane Versus Herceptin Plus Taxane as First Line Therapy in Patients With HER2-Positive Metastatic Breast Cancer

Trial Profile

A Multicenter, Double-Blind, Randomized, Parallel-Group, Phase III Study of the Efficacy and Safety of Hercules Plus Taxane Versus Herceptin Plus Taxane as First Line Therapy in Patients With HER2-Positive Metastatic Breast Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2019

At a glance

  • Drugs Trastuzumab (Primary) ; Docetaxel; Paclitaxel
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms HERITAGE
  • Sponsors Mylan
  • Most Recent Events

    • 04 Jun 2019 Results assessing safety and overall survival during maintenance, cumulative through 36 months of follow-up from last patient on study (final overall survival), were presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 15 May 2019 According to a Mylan media release, data from the study will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
    • 05 Nov 2018 This trial has been completed in Latvia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top